

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Potassium iodide (jellies)

December 17, 2024

Therapeutic category

Mineral preparations

Non-proprietary name

Potassium iodide (jellies)

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

Current	Revision												
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) <u>Patients receiving eplerenone (hypertension) or esaxerenone</u>	2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) (deleted)												
10. INTERACTIONS <u>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</u>	10. INTERACTIONS (deleted)												
<table><tr><th><u>Drugs</u></th><th><u>Signs, symptoms, and treatment</u></th><th><u>Mechanism/risk factors</u></th></tr><tr><td><u>Eplerenone (for hypertension)</u> <u>Esaxerenone</u></td><td><u>Serum potassium levels may increase.</u></td><td><u>Potassium retention effect may be enhanced due to co-administration.</u></td></tr></table>	<u>Drugs</u>	<u>Signs, symptoms, and treatment</u>	<u>Mechanism/risk factors</u>	<u>Eplerenone (for hypertension)</u> <u>Esaxerenone</u>	<u>Serum potassium levels may increase.</u>	<u>Potassium retention effect may be enhanced due to co-administration.</u>							
<u>Drugs</u>	<u>Signs, symptoms, and treatment</u>	<u>Mechanism/risk factors</u>											
<u>Eplerenone (for hypertension)</u> <u>Esaxerenone</u>	<u>Serum potassium levels may increase.</u>	<u>Potassium retention effect may be enhanced due to co-administration.</u>											
10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)	10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)												
<table><tr><th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/risk factors</th></tr><tr><td>Eplerenone <u>(for chronic heart failure)</u> Finerenone</td><td>Serum potassium levels may increase. Careful attention should be paid such as monitoring serum potassium levels periodically.</td><td>Potassium retention effect may be enhanced.</td></tr></table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Eplerenone <u>(for chronic heart failure)</u> Finerenone	Serum potassium levels may increase. Careful attention should be paid such as monitoring serum potassium levels periodically.	Potassium retention effect may be enhanced.	<table><tr><th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/risk factors</th></tr><tr><td>Eplerenone <u>Esaxerenone</u> Finerenone</td><td>Serum potassium levels may increase. Careful attention should be paid such as monitoring serum potassium levels periodically.</td><td>Potassium retention effect may be enhanced.</td></tr></table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Eplerenone <u>Esaxerenone</u> Finerenone	Serum potassium levels may increase. Careful attention should be paid such as monitoring serum potassium levels periodically.	Potassium retention effect may be enhanced.
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors											
Eplerenone <u>(for chronic heart failure)</u> Finerenone	Serum potassium levels may increase. Careful attention should be paid such as monitoring serum potassium levels periodically.	Potassium retention effect may be enhanced.											
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors											
Eplerenone <u>Esaxerenone</u> Finerenone	Serum potassium levels may increase. Careful attention should be paid such as monitoring serum potassium levels periodically.	Potassium retention effect may be enhanced.											